Latest News Feeds
The Chartered Institute of Public Finance and Accountancy (CIPFA) -
This paper looks at whether the Government have adequate plans to deal with the financial pressures on the health service. It reviews the evidence by looking at recent financial results and forecasts and the pressures they indicate, making comparisons with trends in spending levels and analysing the specific pressures likely in future years. Current plans are based on the NHS’s Five Year Forward View’s assessment that £30bn of pressures are faced over the five years to 2021, and that £8bn of that will be offset by additional funding. CIPFA concludes that the key figures of £30bn pressures and £22bn savings are both optimistic and makes recommendations for how the Government can improve the realism of the plans, and what actions it should take to make any plan a more deliverable reality.
Local Government Association (LGA) -
This guidance produced by the LGA in collaboration with the community interest company Innovations in Dementia outlines the important role of councils in supporting people with dementia by creating local dementia friendly communities and demonstrates how councils are making this happen through numerous case study examples.
Evaluation of a continuous monitoring and feedback initiative to improve quality of anaesthetic care: a mixed-methods quasi-experimental study
National Institute for Health Research -
This study evaluated the impact of a continuous quality monitoring and feedback initiative in anaesthesia. The results support the potential of quality monitoring and feedback interventions as quality improvement mechanisms and provide insight into the positive response of clinicians to this type of initiative, including documentation of the experiences of anaesthetists that participated as users and codesigners of the feedback.
Office of Health Economics (OHE) -
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.
Please note this item requires free registration for full-text access.
This three year project aimed to investigate how commissioners negotiated, specified, monitored and managed contractual mechanisms to improve services and allocate financial risk in their local health economies, looking at both acute services and community health care.